Blood-Brain Barrier: Considerations in Drug Development and Delivery

Chemical Biology: Approaches to Drug Discovery and Development to Targeting Disease

Volumn , Issue , 2012, Pages 133-146

  Miller, David S ^a   Hawkins, Brian T ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

BBB in drug development and delivery; BBB phenotype, an emergent property of the endothelium; BBB transient structural for drug permeability, retaining therapeutic; BBB, unique biological physicochemical characteristics; Drug delivery to brain, severity in CNS disorder pharmacotherapy

Indexed keywords

EID: 84886682685     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118435762.ch8     Document Type: Chapter

References (32)

1. Pardridge WM. Drug targeting to the brain. Pharm. Res. 2007;24:1733-1744.
2. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005;57:173-185.
3. Stewart PA, Wiley MJ. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras. Dev. Biol. 1981;84:183-192.
4. Calabria AR, Shusta EV. A genomic comparison of in vivo and in vitro brain microvascular endothelial cells. J. Cereb. Blood Flow Metab. 2008;28:135-148.
5. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl. Physiol. 2006;100:1059-1064.
6. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat. Neurosci. 2007;10:1369-1376.
7. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28:5-11.
8. Hjort N, Wu O, Ashkanian M, Solling C, Mouridsen K, Christensen S, Gyldensted C, Andersen G, Ostergaard L. MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke 2008;39:1025-1028.
9. Hawkins BT, Egleton RD. Pathophysiology of the blood-brain barrier: animal models and methods. Curr. Top Dev. Biol. 2008;80:277-309.
10. Nagaraja TN, Keenan KA, Brown SL, Fenstermacher JD, Knight RA. Relative distribution of plasma flow markers and red blood cells across BBB openings in acute cerebral ischemia. Neurol. Res. 2007;29:78-80.
11. Miller DS, Bauer B, Hartz AM. Modulation of p-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev. 2008;60:196-209.
12. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 2006;58:140-161.
13. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 2007;25:2306-2312.
14. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005;6:591-602.
15. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci. 2006;9:487-488.
16. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther. 2008;325:349-356.
17. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx. 2005;2:15-26.
18. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and bloodcerebrospinal fluid barriers. Adv. Exp. Med. Biol. 2001;500:365-372.
19. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083-1099; discussion 1099-1100.
20. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull. 2003;60:297-306.
21. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008;73:1444-1453.
22. Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J. Med. Chem. 2006;49:7559-7583.
23. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 2007;24:1772-1787.
24. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptormediation. Pharm. Res. 2007;24:1759-1771.
25. Xia CF, Zhang Y, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res. 2007;24:2309-2316.
26. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43.
27. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 2007;104:7594-7599.
28. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol. Neurobiol. 2005;25:5-23.
29. Abbott NJ, Ronnback L, and Hansson E. Astrocyte-endothelial interactions at the bloodbrain barrier. Nat. Rev. Neurosci. 2006;7:41-53.
30. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004;104:29-45.
31. Lok J, Gupta P, Guo S, Kim WJ, Whalen MJ, van Leyen K, Lo EH. Cell-cell signaling in the neurovascular unit. Neurochem. Res. 2007;32:2032-2045. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. 2006;7:183-203.
32. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178-201.